Kurome Therapeutics
Biotechnology, 3536 Edwards Road Suite 100, Cincinnati, Ohio, 45208, United States, 1-10 Employees
Phone Number: +15*********
Who is KUROME THERAPEUTICS
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subve...
Read More
-
Headquarters: 3536 Edwards Road Suite 100, Cincinnati, Ohio, 45208, United States
-
Date Founded: 2019
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Jan Rosenbaum
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from KUROME THERAPEUTICS
Kurome Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Kurome Therapeutics
Answer: Kurome Therapeutics's headquarters are located at 3536 Edwards Road Suite 100, Cincinnati, Ohio, 45208, United States
Answer: Kurome Therapeutics's phone number is +15*********
Answer: Kurome Therapeutics's official website is https://kurometherapeutics.com
Answer: Kurome Therapeutics's revenue is $1 Million to $5 Million
Answer: Kurome Therapeutics's SIC: 2834
Answer: Kurome Therapeutics's NAICS: 325412
Answer: Kurome Therapeutics has 1-10 employees
Answer: Kurome Therapeutics is in Biotechnology
Answer: Kurome Therapeutics contact info: Phone number: +15********* Website: https://kurometherapeutics.com
Answer: Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms. Kurome Therapeutics is a preclinical stage company that is developing a series of IRAK1/4, panFLT3 inhibitors. Preclinical studies have demonstrated: -Broad range of efficacy in MDS and AML patient-derived cell lines -Synergy with Venclexta (Venetoclax) to improve Venclexta potency -Identification of a biomarker that correlates with prognosis in AML patients and maximal activation of immune signaling through this pathway in AML cells -Increased overall survival in cell line and patient-derived xenograft models, well beyond that of existing FLT3 inhibitors -Maintenance of complete efficacy even in settings of adaptive resistance to FLT3 inhibitors and in settings of FLT3 mutations Kurome Therapeutics is founded on research developed in the laboratory of Dr. Daniel Starczynowski at Cincinnati Children's Hospital Medical Center in collaboration with the National Center for Advancing Translational Sciences (NCATS) at the NIH.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month